Notice2024-00695
Request for Information Inviting Input on an NIH-Wide Strategic Plan for Autoimmune Disease Research
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 16, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The purpose of this Request for Information (RFI) is to invite input on the development of a National Institutes of Health (NIH)-wide strategic plan to advance autoimmune disease research. NIH is seeking input from members of the scientific community, Federal partners, academic institutions, the private sector, health professionals, professional societies, advocacy groups, patient communities, and other interested members of the public.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 10 (Tuesday, January 16, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 10 (Tuesday, January 16, 2024)]
[Notices]
[Pages 2626-2627]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-00695]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information Inviting Input on an NIH-Wide Strategic
Plan for Autoimmune Disease Research
AGENCY: National Institutes of Health, HHS.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: The purpose of this Request for Information (RFI) is to invite
input on the development of a National Institutes of Health (NIH)-wide
strategic plan to advance autoimmune disease research. NIH is seeking
input from members of the scientific community,
[[Page 2627]]
Federal partners, academic institutions, the private sector, health
professionals, professional societies, advocacy groups, patient
communities, and other interested members of the public.
DATES: The NIH-wide Strategic Plan for Autoimmune Disease Research
Request for Information is open for public comment through March 1,
2024. Comments must be received by March 1, 2024, to ensure
consideration. Comments received after the public comment period has
closed may be considered by the Office of Autoimmune Disease Research
within the Office of Research on Women's Health.
ADDRESSES: Submissions must be submitted electronically via the
following website: <a href="https://rfi.grants.nih.gov/?s=656f78c997c67a6239036b22">https://rfi.grants.nih.gov/?s=656f78c997c67a6239036b22</a>.
FOR FURTHER INFORMATION CONTACT: Questions about this request for
information should be directed to Vicki Shanmugam, MBBS, MRCP, FACR,
CCD, Director, Office of Autoimmune Disease Research, Office of
Research on Women's Health, 6707 Democracy Boulevard, Bethesda, MD
20892, <a href="/cdn-cgi/l/email-protection#0d626c697f20627f7a652e7f6b644d626923636465236a627b">oadr-orwh#<span class="__cf_email__" data-cfemail="93e1f5fad3fcf7bdfdfafbbdf4fce5">[email protected]</span></a>, 301-402-1770.
SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st
Century Cures Act, wherein NIH and its institutes are required to
regularly update their strategic plans. In 2022, the National Academies
of Sciences, Engineering, and Medicine report, Enhancing NIH Research
on Autoimmune Diseasehttps://pubmed.ncbi.nlm.nih.gov/35593778/%22%20/
l%20%22:~:text=Enhancing%20NIH%20Research%20on%20Autoimmune%20Disease%20
also%20calls,years%29%20to%20study%20disease%20across%20the%20life%20cou
rse, examined NIH research efforts related to autoimmune diseases.
Subsequently, Congress, via the Joint Explanatory Statement <a href="https://www.appropriations.senate.gov/imo/media/doc/Division%20H%20-%20LHHS%20Statement%20FY23.pdf">https://www.appropriations.senate.gov/imo/media/doc/Division%20H%20-%20LHHS%20Statement%20FY23.pdf</a> accompanying the Fiscal Year 2023
Consolidated Appropriations Act, 2023 directed the establishment of an
Office of Autoimmune Disease Research<a href="https://orwh.od.nih.gov/">https://orwh.od.nih.gov/</a>oadr-orwh
within the Office of Research on Women's Health (OADR-ORWH) <a href="https://orwh.od.nih.gov/">https://orwh.od.nih.gov/</a> and directed OADR-ORWH to:
<bullet> Coordinate development of a multi-institute and center
(IC) strategic research plan;
<bullet> Identify emerging areas of innovation and research
opportunity;
<bullet> Coordinate and foster collaborative research across ICs;
<bullet> Annually evaluate the NIH autoimmune disease research
portfolio;
<bullet> Provide resources to support planning, collaboration, and
innovation; and
<bullet> Develop a publicly accessible central repository for
autoimmune disease research.
Currently, various NIH institutes, centers, and offices (ICOs)
support autoimmune disease research in alignment with their individual
mission areas. Establishing an NIH-wide Strategic Plan for Autoimmune
Disease Research will allow OADR-ORWH to amplify ICO efforts and create
opportunities for synergistic innovation focused on areas of autoimmune
disease research that will benefit from multi-ICO partnerships and
opportunities to implement cross-cutting research.
Information Requested
NIH is seeking input from internal and external partners throughout
the scientific research, advocacy, and clinical practice communities,
including those employed by NIH and by institutions receiving NIH
support, as well as the public, on the following key areas related to
autoimmune disease research:
Objective 1: Research areas that would benefit from cross-cutting,
collaborative research (these areas may include basic or translational
research, clinical research, health services research, population
science, data science, preventative research, biomedical engineering,
and other areas of research).
Objective 2: Opportunities to advance collaborative, innovative, or
interdisciplinary areas of autoimmune disease research.
Objective 3: Opportunities to improve outcomes for individuals
living with autoimmune diseases including NIH-designated health
disparities populations https://<a href="http://www.nimhd.nih.gov/about/overview/">www.nimhd.nih.gov/about/overview/</a>,
populations and individuals with rare diseases, and specific
populations that have been historically underrepresented in research
and clinical trials.
Objective 4: Cross-cutting areas that are integral to advancing
autoimmune disease research at NIH including development of a publicly
accessible central repository for autoimmune disease research, sex- and
gender-intentional research design across all stages of research, and
engagement of all populations in research and clinical trials.
Responses to this RFI are voluntary and are meant for information
and planning purposes only. Do not include any proprietary, classified,
confidential, trade secret, or sensitive information in your response.
Respondents are advised that the responses are reviewed by NIH staff,
and the U.S. government is under no obligation to acknowledge receipt
of the information provided or provide feedback to the respondents.
This RFI is for planning purposes only and should not be construed as a
solicitation, grant, or cooperative agreement, or as an obligation on
the part of the federal government, the NIH, or individual NIH
institutes, centers, and offices to provide any kind of support for any
ideas identified in response to it.
The government may use the information submitted in response to
this RFI at its discretion. The government reserves the right to use
any submitted information on public NIH websites, in reports, in
summaries of the state of the science, in any possible resultant
solicitation(s), grant(s), or cooperative agreement(s), or in the
development of future funding announcements.
The government will not pay for the preparation of any information
submitted or for the government's use of such information. No basis for
claims against the U.S. government shall arise as a result of a
response to this request for information or from the government's use
of such information.
NIH looks forward to your input, and we hope that you will share
this RFI document with your colleagues.
Dated: January 6, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes of Health.
[FR Doc. 2024-00695 Filed 1-12-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 16, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.